A drug that inhibits DNA-modifying enzymes makes stubborn lymphoma cells sensitive to chemotherapy.
A team led by Leandro Cerchietti and Ari Melnick of Weill Cornell Medical College in New York studied drugs that prevent DNA methylation, a modification that 'silences' genes. Work in cell lines and mouse models for diffuse large B-cell lymphoma (DLBCL) showed that such a drug reactivated genes that made the anti-cancer agent doxorubicin more effective. Twelve patients with DLBCL were given an anti-methylation drug and standard chemotherapy; 11 responded. Biopsies showed decreased methylation and increased activity of a gene called SMAD1, which is often silenced in resistant DLBCL. The results suggest that targeting excessive DNA methylation could reverse treatment resistance.
Rights and permissions
About this article
Cite this article
Revived genes give therapy a boost. Nature 500, 504 (2013). https://doi.org/10.1038/500504d
Published:
Issue Date:
DOI: https://doi.org/10.1038/500504d